– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,…
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE…
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D.,…
A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in…
Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Aug.…
The combination of data and analytics will accelerate pharmaceutical breakthroughs by helping clinical trial teams uncover the best sites and…
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose…
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,…
Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a buttonREDWOOD…